Opendata, web and dolomites

SIGNIA

SIGNIA: An innovative drug discovery platform for rapid identification and validation of antimicrobial applications in available pharmaceutical resources and drugs open for repurposing.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIGNIA project word cloud

Explore the words cloud of the SIGNIA project. It provides you a very rough idea of what is the project "SIGNIA" about.

market    platform    capacity    avoids    viruses    lose    mutability    pharma    commercialized    rate    industry    independent    safer    novo    selects    antimicrobial    encloses    mers    identification    huge    preparation    discovery    released    outbreaks    costly    25    annually    becomes    deaths    preparedness    compounds    world    resistant    fast    infections    antigenic    microbe    efficient    cell    alters    emerged    stage    burden    recycling    responsible    signia    selecting    resistance    phenomenon    roi    urgent    antimicrobials    consuming    antivirals    billion    decade    offers    finalise    accelerate    impacts    trl6    society    libraries    drugs    pathogens    social    pathogen    validated    economic    influenza    sars    once    functional    efficacy    paradigm    outpacing    impacting    time    reached    intrinsic    infected    drug    company    instead    de    organisms    causative    costing    spectrum    faster    emergence    broad    strain    pose    therapeutics    roadmap    threat    advantages    enhanced    hindering    mutation    originally    repurposing    determinants   

Project "SIGNIA" data sheet

The following table provides information about the project.

Coordinator
SIGNIA THERAPEUTICS 

Organization address
address: L'ATRIUM 43 BOULEVARD DU 11 NOVEMBRE 1918
city: VILLEURBANNE
postcode: 69100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://signiatherapeutics.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIGNIA THERAPEUTICS FR (VILLEURBANNE) coordinator 50˙000.00

Map

 Project objective

The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens. This phenomenon is outpacing the industry’s capacity for drug discovery and development. Antimicrobial resistance is costing the EU today €1.5 billion and 25,000 deaths annually. Developing de novo classical drugs is very costly and time consuming, and for every new drug released a resistant strain has rapidly emerged. This paradigm is hindering our ability to respond to outbreaks. Among causative organisms, viruses pose a major threat, being responsible for the outbreaks impacting the world in the past decade (SARS, Influenza A, MERS, etc). Although some antivirals have been developed for them, they lose their efficacy rapidly due to the high mutation rate of viruses, which alters the antigenic features originally used to develop the drug. Thus, there is an urgent need for novel discovery methods that allow to accelerate the development of broad-spectrum and mutability-independent antimicrobials. In response, Signia Therapeutics has developed and validated a drug discovery platform for fast identification of compounds with antimicrobial activity. Instead of selecting drugs that target pathogen determinants, it selects drugs that target determinants of the infected cell. This method offers key advantages: i) avoids the impact of microbe intrinsic mutability; ii) broad spectrum drugs can be identified. Since the platform seeks for antimicrobial applications among drugs already commercialized (repurposing) and among pharma libraries (recycling), drug discovery becomes faster, safer and cost-efficient. Having reached the functional stage (TRL6), this project encloses the roadmap to finalise the platform’s development and its preparation for market. Once completed, this project will have huge impacts for society (better management of infections and preparedness against outbreaks), and for our company (expected ROI of €2.1 from this project after 5 years).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIGNIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIGNIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More